FindTrial
Sign In

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients With HIV-1 Infection (the Tipranavir Expanded Access Program)

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT00097799
Enrollment
Unknown
Registered
2004-12-01
Start date
2004-12-31
Completion date
Unknown
Last updated
2016-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Brief summary

This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.

Interventions

DRUGTipranavir

500 mg twice daily

DRUGRitonavir

200 mg twice daily

Sponsors

Boehringer Ingelheim
Lead SponsorINDUSTRY

Eligibility

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026